Status:
COMPLETED
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degare...
Detailed Description
Participants who completed the main FE200486 CS14 study initially continued with the same dose in the FE200486 CS14A extension study. A protocol amendment changed the dosage to 160 mg (40 mg/mL) for a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Has given written consent prior to any study-related activity being performed. A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient.
- Has completed study FE200486 CS14 through visit 22.
- Exclusion Criterion:
- Has been withdrawn from the FE200486 CS14 study.
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00117286
Start Date
March 1 2005
End Date
November 1 2009
Last Update
December 18 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
2
Advanced Urology Medical Center
Anaheim, California, United States, 92801
3
West Coast Clinical Research
Tarzana, California, United States, 91356
4
Western Clinical Research
Torrance, California, United States, 90505